FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Promising efficacy of coenzyme Q10 supplementation as adjunctive therapy in juvenile idiopathic arthritis: a randomized-controlled pilot study. PMID 41958203 · Immunopharmacol Immunotoxicol · 2026-Jun This record is an original randomized controlled trial (Phase II/III) in humans, but it fails multiple key eligibility criteria: 1) It is not an oncology/malignant neoplasm study (juvenile idiopathic arthritis). 2) The intervention is a dietary supplement (CoQ10), not a drug. 3) The primary efficacy endpoint is a disease activity score (JADAS-10), not a time-to-event endpoint like OS, PFS, etc. No Kaplan-Meier or HR is reported. Therefore, it is ineligible. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. PMID 41958186 · J Child Adolesc Psychopharmacol · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of scalp cooling system versus chemical cooling cap in preventing chemotherapy-induced alopecia in breast cancer (COHAIR Study): a prospective randomized trial. PMID 41955993 · Breast · 2026-Jun The trial is a randomized, prospective study in oncology patients, but its primary efficacy endpoint is the prevention of chemotherapy-induced alopecia (a supportive care outcome), not a key time-to-event efficacy endpoint (like OS, PFS, DFS) for the cancer itself. The mention of DFS as comparable is incidental and not the primary focus. The trial phase is not confirmed to be Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. PMID 41954860 · Adv Ther · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial. PMID 41953358 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy for obstructive colon cancer derived by a stoma: Study protocol of the FRENCH-01 randomized phase III trial (COnCERTO Trial). PMID 41945039 · Dig Liver Dis · 2026-Jun 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41944053 · J Child Adolesc Psychopharmacol · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aficamten: First Approval. PMID 41941083 · Drugs · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol summary and statistical analysis plan for the bone loss prevention with zoledronic acid or denosumab in critically ill adults (BONE ZONE) trial. PMID 41940313 · Crit Care Resusc · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| STRASS 2 target trial emulation: Bridging the gap between trial efficacy and real-world effectiveness. PMID 41936769 · Surgery · 2026-Jun The record is a target trial emulation study using real-world data to evaluate the STRASS 2 trial's concept. It is not the original report of a Phase III/IIIb or Phase II/III randomized clinical trial. The study itself is observational and retrospective, not a prospective randomized trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis. PMID 41936548 · Obesity (Silver Spring) · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review. PMID 41935608 · J Gastrointest Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials. PMID 41935547 · Eur J Pharm Biopharm · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. PMID 41934464 · J Thorac Oncol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial. PMID 41932350 · Lancet Gastroenterol Hepatol · 2026-Jun The trial is a Phase 3 randomized oncology trial with a primary OS endpoint and HR, but it compares two surgical techniques (robot-assisted vs. conventional minimally invasive esophagectomy). It lacks a drug-containing intervention as required for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial. PMID 41922627 · Clin Rheumatol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. PMID 41917160 · Nat Med · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase III Prospective Randomised Study of Netarsudil and Concomitant Latanoprost Efficacy and Safety for Primary Open-Angle Glaucoma or Ocular Hypertension in Japan: J-ROCKET-2. PMID 41915113 · Adv Ther · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of oral nutritional supplements on nutritional outcomes and survival in post-gastrectomy patients receiving chemotherapy. PMID 41912109 · Clin Nutr ESPEN · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Four-Factor Prothrombin Complex Concentrate Versus Plasma in Patients on Vitamin K Antagonists Undergoing Urgent Orthopedic Surgery: A Post Hoc Analysis. PMID 41910938 · Adv Ther · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial. PMID 41910935 · Adv Ther · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach. PMID 41906858 · Diabetes Obes Metab · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT. PMID 41905637 · Radiother Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies. PMID 41903881 · J Allergy Clin Immunol Pract · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. PMID 41903611 · Radiother Oncol · 2026-Jun 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial. PMID 41896701 · BJU Int · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. PMID 41883295 · Diabetes Obes Metab · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| KORT - Knee osteoarthrosis radiotherapy trial: Protocol for a multidisciplinary pathway and a planned sham-controlled phase III trial of low-dose radiotherapy in knee osteoarthritis. PMID 41859527 · Osteoarthr Cartil Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Host-directed therapy for tuberculosis: Repurposed drugs toward global tuberculosis elimination. PMID 41856464 · Int J Infect Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents. PMID 41849920 · Psychiatry Res · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A multidomain perioperative intervention improves postoperative recovery and clinical outcomes after abdominoperineal resection for low rectal cancer: A randomized controlled trial. PMID 41849835 · Am J Surg · 2026-Jun The trial is a randomized, human, oncology study with a primary time-to-event endpoint (DFS). However, the intervention is a non-drug behavioral/cognitive therapy integrated into ERAS, not a drug-containing intervention, which is a required criterion. There is also no explicit evidence of Phase III/IIIb or Phase II/III status in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical and metabolic benefits of efruxifermin in MASH: a GRADE-assessed meta-analysis of randomized trials with trial sequential analysis. PMID 41843368 · Hepatol Int · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial. PMID 41840328 · Rheumatol Ther · 2026-Jun 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials. PMID 41839399 · Crit Rev Oncol Hematol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial. PMID 41833659 · Metabolism · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Active immunization strategies in glioblastoma - clinical outcomes and effect modifiers for dendritic vaccines and adoptive cell therapies: a systematic review. PMID 41833230 · J Clin Neurosci · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long‑term outcomes of prophylactic cranial irradiation in high‑risk metastatic NSCLC: Final PRoT‑BM analysis. PMID 41831620 · Radiother Oncol · 2026-Jun The study is a randomized Phase II trial in oncology with time-to-event endpoints, but it evaluates a radiation intervention (prophylactic cranial irradiation) without a drug-containing arm, failing the drug intervention criterion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Pain Relief in Patients Undergoing Elective Laparoscopic Gastrointestinal Tumor Surgery. PMID 41824217 · Pain Ther · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. PMID 41821360 · Prostate · 2026-Jun The study is a randomized, human, oncology-related trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The analysis focuses on LUTS incidence/progression as a secondary outcome, making it ineligible for the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41817930 · Ann Surg Oncol · 2026-Jun The trial is a Phase 3, randomized, placebo-controlled oncology trial with a drug intervention. However, based on the provided metadata (title indicates it's about surgical outcomes after neoadjuvant treatment), the primary or key secondary endpoint appears to be a pathological/surgical outcome (e.g., pathological complete response), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it fails the 'time_to_event' criterion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study. PMID 41814037 · Rheumatol Ther · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem‑ion): Interim report of a randomized phase II pilot trial. PMID 41812864 · Radiother Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study. PMID 41801560 · Int J Hematol · 2026-Jun 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. PMID 41796863 · J Thorac Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial. PMID 41796854 · J Pediatr · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced pancreatic cancer: A single-center randomized controlled trial. PMID 41794391 · Clin Nutr ESPEN · 2026-Jun The record is a Phase II/III randomized trial (indicated by trial registration UMIN000028659, which is a Phase III study) with a drug-containing intervention (chemotherapy) and primary time-to-event efficacy endpoints (OS, PFS). However, the specific intervention being evaluated (elemental diet) is a nutritional supplement, not a drug. The cohort definition requires a 'drug-containing intervention' as the key element of the trial. While chemotherapy is present in both arms, the trial is designed to evaluate the effect of adding an elemental diet to standard chemotherapy. The primary intervention is not a drug. Therefore, it is excluded based on the 'drug_intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial. PMID 41790076 · Gastroenterology · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Short-term isolated leucine supplementation was not associated with improvements in muscle mass or function in patients with head and neck cancer: A randomized, double-blind, proof-of-concept trial with an elderly non-cancer comparator cohort. PMID 41786247 · Clin Nutr ESPEN · 2026-Jun The study is a randomized, double-blind, proof-of-concept trial evaluating leucine supplementation for cancer cachexia. It is oncology-related, human, randomized, and has a drug intervention. However, it is not a Phase III/IIIb or Phase II/III trial (it's a proof-of-concept study), and its primary endpoint is change in muscle mass (a biological/functional measure), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the core eligibility criteria for this adjudication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome. PMID 41784472 · Epilepsia · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. PMID 41780642 · Ann Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |